longitudinal clinical outcomes of tau-pet-positive individuals
Published 1 year ago • 68 plays • Length 9:01Download video MP4
Download video MP3
Similar videos
-
2:37
time gap between amyloid- and tau-pet positivity in preclinical disease
-
1:29
limitations of [18f]flortaucipir tau-pet imaging
-
40:49
dr. ossenkoppele - tau pet
-
0:51
current and future role of tau-pet in dementia daily practice
-
1:45
promise of tau-pet imaging for alzheimer's disease
-
13:13
all about pet scans and alzheimer's disease
-
24:37
what causes alzheimer's disease: amyloid vs tau
-
11:28
targeting tau in alzheimer's disease
-
2:51
association of csf and plasma biomarkers with longitudinal tau accumulation
-
2:11
tau ligands and the future of tau pet imaging
-
3:53
why does tau-pet not detect the earliest stages of alzheimer’s disease?
-
2:02
tau pet imaging: the current landscape
-
6:32
the role of tau in autosomal dominant alzheimer’s disease
-
2:27
a new aβ pet-based staging method
-
1:56
advantages of tau-pet compared to amyloid-pet
-
1:06
the promise of 4r tau-pet tracer development
-
1:14
research highlight: toxic tau aggregates determines type of dementia
-
1:08
why alzheimer’s disease research is focusing on tau
-
2:57
clinical outcome assessments for clinical trials in rare tauopathies
-
3:36
the importance of new methods for monitoring tau pathology
-
1:28
next generation tau tracers: [18f]mk-6420 vs [18f]flortaucipir
-
5:31
the spreading pathways of tau and amyloid